Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Vanaclocha

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2014
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registryG Carretero, C Ferrandiz, E Dauden, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysisP Dávila-Seijo, E Dauden, G Carretero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2013
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm RegistryJ M Carrascosa, M Vilavella, I Garcia-Doval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2017
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registryA Pérez-Plaza, G Carretero, C Ferrandiz, et al.
Actas Dermo-Sifiliograficas|September 24, 2016
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm RegistryS Galiano Mejías, G Carretero, C Ferrandiz, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2014
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registryG Carretero, C Ferrandiz, E Dauden, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysisP Dávila-Seijo, E Dauden, G Carretero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2013
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm RegistryJ M Carrascosa, M Vilavella, I Garcia-Doval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2017
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registryA Pérez-Plaza, G Carretero, C Ferrandiz, et al.
Actas Dermo-Sifiliograficas|September 24, 2016
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm RegistryS Galiano Mejías, G Carretero, C Ferrandiz, et al.
Pageof 11